CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 20 pages
ACIP 2025 BusinessThimerosal as a Vaccine Preservative Prepared for the Advisory Committee for Immunization PracticesLyn Redwood RN, MSN, FP (Retired) 2The Food and Drug Administration Modernization Act of 1997 •Compiled list of drugs and foods that contained intentionally introduced mercury compounds •Provided quantitative and qualitative analysis of mercury compounds •Report included 219 products which included 11 biologics and immunoglobulin therapies Ref: U.S. Congress. (1997,…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 37 pages
Partial Evidence to Recommendations for use of chikungunya vaccines among persons in U.S. territories at risk for chikungunya virus transmissionNational Center for Emerging and Zoonotic Infectious Diseases Dr. Lyle Petersen Director, Division of Vector -Borne Diseases Advisory Committee on Immunization Practices meeting June 26, 2025 •Two licensed chikungunya vaccines -Live attenuated vaccine licensed in November 2023 for use in persons aged ≥18 years (manufactured by Valneva) -Virus…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 4 pages
Introduction to the Anthrax Vaccine Work Group Brendan Jackson, MD, MPH Captain, U.S. Public Health Service Principal Deputy Director Division of High -Consequence Pathogens and Pathology June 26, 2025 Advisory Committee on Immunization PracticesNational Center for Emerging and Zoonotic Infectious Diseases •Bacillus anthracis , the causative agent of anthrax, is an endospore -forming bacterium found naturally in soil around the world •Humans are most often infected by exposure to infected…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 12 pages
1 MMRV Vaccine Safety Contents Summary ................................ ................................ ................................ ................................ ...... 1 Cochrane Review ................................ ................................ ................................ ........................... 2 General safety ................................ ................................ ................................ ............................... 3 Febrile…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 13 pages
MMRV MMRV = One combined shot for Measles, Mumps, Rubella and Varicella alternative to MMR+V = Two shots, one for Measles, Mumps and Rubella and another for Varicella No known difference in efficacy MMRV Timeline 2005: FDA licensed the combined MMRV vaccine for use in children 12 months to 12 years of age. 2006: The CDC Advisory Committee on Immunization Practices recommended use of MMRV, with preference over separate MMR and Varicella vaccines. Weekly Safety Surveillance CDC’s…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 23 pages
Agency for Toxic Substances and Disease Registry National Center for Environmental Health Centers for Disease Control and Prevention Mpox Vaccine Work Group Faisal Syed Minhaj, PharmD, MPH Poxvirus and Rabies Branch Centers for Disease Control and Prevention ACIP Meeting April 15, 2025 •Genus: Orthopoxvirus •Family: Poxviridae •Discovered in 1958 after two pox-like disease outbreaks in research monkey colonies •Specific animal reservoir unknown, but likely African small mammals •On…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 26 pages
! "# " $%$& ' ( ) * +,- ., / 0 * &/ ( $ , / 1 2 3 $& ' 4 &$)5 6 -. &2) 4 &$/ 7$ 88 &$/ - *9 :; <
;= > ? @ ; A: ;;
;; ; B ;…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 56 pages
Agency for Toxic Substances and Disease Registry National Center for Environmental Health Centers for Disease Control and Prevention Evidence to Recommendations Framework: Vaccination with Jynneos for Adolescents at Risk of Mpox During Outbreaks Faisal Syed Minhaj, PharmD, MPH Poxvirus and Rabies Branch Centers for Disease Control and Prevention Advisory Committee on Immunization Practices April 15, 2025 •Structure to describe information considering in moving fr om evidence to ACIP…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 41 pages
Agency for Toxic Substances and Disease Registry National Center for Environmental Health Centers for Disease Control and Prevention Evidence to Recommendations Framework: Routine Vaccination with Jynneos for Adolescents at Risk of Mpox Faisal Syed Minhaj, PharmD, MPH Poxvirus and Rabies Branch Centers for Disease Control and Prevention Advisory Committee on Immunization Practices April 15, 2025 Does ACIP recommend vaccination* with the 2-dose †JYNNEOS vaccine series for persons aged…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 7 pages
Introduction to the Lyme Disease Vaccines Work Group Grace E. Marx, MD, MPH Lead, Lyme Disease Vaccines Work Group April 15, 2025 Advisory Committee on Immunization PracticesNational Center for Emerging and Zoonotic Infectious Diseases •Most common vector -borne disease in the U.S. •An estimated 476,000 people in the U.S. diagnosed and treated for Lyme disease each year1 •Estimated to cost $345– 968 million annually in health care costs2Public Health Problem –Lyme disease 1. Kugeler K et…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 22 pages
Highly Pathogenic Avian Influenza A (H5N1) Tom Shimabukuro, MD, MPH, MBA Influenza Division National Center for Immunization and Respiratory Diseases (NCIRD) Centers for Disease Control and Prevention (CDC) October 23, 2024 HPAI A(H5N1)/ HPAI A(H5) Human Cases Since 1997 Past Reported Global Human Cases with Highly Pathogenic Avian Influenza A(H5N1) (HPAI H5N1) by Country, 1997 -2024 | Bird Flu | C DC (Thru Aug 7, 2024; may include A(H5)+, presumed H5N1 cases) 2 •Historically, human…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 6 pages
CHIKUNGUNYA VACCINES ACIP Meeting October 23, 2024 Edwin Asturias, MD Chair, ACIP Chikungunya Vaccines Work Group •Chikungunya Vaccines Work Group formed in May 2022 •Chikungunya vaccines -Live attenuated vaccine licensed in November 2023 (manufactured by Valneva) -Virus -like particle vaccine submitted to FDA for licensure (manufactured by Bavarian Nordic) •Some recommendations developed, and others under development, for use of chikungunya vaccines among U.S. persons at risk of…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 16 pages
Update on chikungunya and chikungunya vaccinesNational Center for Emerging and Zoonotic Infectious Diseases Susan Hills MBBS MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP Meeting, October 23, 2024 •Mosquito -borne disease •Key vectors are Aedes aegypti and Aedes albopictus mosquitoesChikungunya 2 Distribution and virus transmission Typically tropical and subtropical regions Periodically causes…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 20 pages
CHIKV VLP vaccine Bavarian Nordic’s chikungunya vaccine candidate October 2024 Victoria Jenkins, PhD, MBA VP Regulatory Affairs & CHIKV Program LeadBavarian Nordic vije@bavarian -nordic.com 2E protein Membrane Capsid shell RNA CHIKV VLP vaccine Chikungunya virus3CHIKV virus -like particle vaccine (CHIKV VLP)1 CHIKV, chikungunya virus; VLP, virus -like particle ; BLA, Biologics License Application; PDUFA, Prescription Drug User Free Act 1. Bennett SR, et al. Lancet Infect Dis.…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 9 pages
Work Group interpretation of data for virus -like particle chikungunya vaccineNational Center for Emerging and Zoonotic Infectious Diseases Susan Hills MBBS MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins , Colorado ACIP Meeting, October 23, 2024 •No vaccine effectiveness data •Short -term* immunogenicity data available from ~2,750 vaccinated subjects in two Phase 3 studies -Majority adults aged 18 –64 years (~2350…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 10 pages
ACIP COVID -19 Vaccines Work Group Robert Schechter, MD COVID -19 ACIP Work Group Chair Advisory Committee on Immunization Practices Meeting October 23, 2024National Center for Immunization and Respiratory Diseases •To protect against COVID -19 disease, caused by SARS -CoV-2, ACIP recommended at its June 2024 meeting the 2024 –2025 COVID -19 vaccines, as authorized or approved by FDA: -Moderna COVID -19 vaccine in persons ≥6 months -Pfizer -BioNTech COVID -19 vaccine in persons ≥6 months…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 27 pages
Implementation Considerations for Additional COVID -19 Vaccine Doses Georgina Peacock, MD, MPH Immunization Services Division Centers for Disease Control and Prevention October 23, 2024National Center for Immunization and Respiratory Diseases COVID -19 Vaccination Coverage and Intent for 2 Doses, National Immunization Survey -Adult COVID Module 2023 -2024 Data 2-Dose Coverage and Intent Among Adults 65 Years and Older COVID -19Vaccination Coverage (≥1 Dose and ≥2 Doses) A mong Adults…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 19 pages
COVID -19–Associated Hospitalizations Update — COVID -NET, July 2023– September 2024 Adults Ages ≥65 Years and Persons with Immunocompromising Conditions Christopher A. Taylor, PhD RESP -NET Hospitalization Surveillance Team Coronavirus and Other Respiratory Viruses Division Meeting of the Advisory Committee on Immunization Practices (ACIP) October 23, 2024National Center for Immunization and Respiratory Diseases 1 COVID -NET is a population -based hospitalization surveillance platform.…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 30 pages
Effectiveness of COVID -19 vaccines Ruth Link -Gelles, PhD, MPH CDR, US Public Health Service Vaccine Effectiveness Program LeadCoronavirus and Other Respiratory Viruses DivisionCenters for Disease Control and Prevention October 23, 2024National Center for Immunization and Respiratory Diseases •VE data to inform need for: -Additional doses in immunocompromised •What’s known about VE in immunocompromised vs. non- immunocompromised adults, including waning by time since dose -Additional dose…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 28 pages
Economic analysis of an additional dose of the 2024 -2025 COVID -19 vaccine University of Michigan COVID -19 Vaccination Modeling Team Presentation to the Advisory Committee on Immunization Practices October 23, 2024 1 Study team University of Michigan •Lisa A. Prosser, PhD, Principal Investigator •David W. Hutton, PhD, Co -Investigator •Acham Gebremariam, MS, Programmer/Analyst •Angela Rose, MS, MPH, Project Manager •Kerra Mercon, MS, Research Assistant Wake Forest University •Cara Janusz,…